- Low-dose semaglutide may reduce alcohol consumption and craving in adults with alcohol use disorder.
- The study, published in JAMA Psychiatry, highlighted potential new treatment applications for the glucagon-like peptide-1 receptor agonist class of medications.
- Participants receiving semaglutide showed significant reductions in laboratory alcohol self-administration and certain drinking outcomes compared with those receiving placebo.
- Semaglutide group also showed greater reductions in cigarettes per day, indicating an unexpected finding.
- The research emphasized the need for larger trials to evaluate glucagon-like peptide-1 receptor agonists for alcohol use disorder treatment.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
